Anebulo Pharmaceuticals (NASDAQ:ANEB) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Anebulo Pharmaceuticals (NASDAQ:ANEB) issued its quarterly earnings data on Wednesday. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Price Performance

Shares of ANEB opened at $1.96 on Friday. The firm has a 50-day simple moving average of $2.05 and a two-hundred day simple moving average of $2.35. The stock has a market cap of $50.83 million, a PE ratio of -5.30 and a beta of -1.01. Anebulo Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $3.61.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.